Vericel Corp- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Vericel Corp 公司

Vericel Corporation 是一家完全整合的商業階段生物製藥公司。該公司爲運動醫學和嚴重燒傷護理市場提供先進療法。它在美國銷售三種產品。MACI（豬膠原膜上的自體培養軟骨細胞）是一種自體細胞化支架產品，用於修復成人有症狀的、一個或多個全層膝關節軟骨缺損（無論是否涉及骨骼）。Epicel（培養的自體表皮移植）是一種永久性皮膚替代品，用於治療深層真皮或全層燒傷面積大於或等於全身表面積 30% 的患者。該公司還持有 NexoBrid（anacaulase-bcdb）的北美權利許可，這是一種含有蛋白水解酶的生物孤兒產品，用於去除成人深層部分厚度和/或全層燒傷的焦痂。

公司簡介

公司代碼VCEL

公司名稱Vericel Corp

上市日期Feb 04, 1997

成立日期1989

CEOMr. Dominick C. Colangelo

員工數量357

證券類型Ordinary Share

年結日Feb 04

公司地址64 Sidney St

城市CAMBRIDGE

上市交易所NASDAQ Global Market Consolidated

國家United States of America

郵編02139

電話17349305555

網址https://vcel.com/

公司代碼VCEL

上市日期Feb 04, 1997

成立日期1989

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. Dominick C. Colangelo

President, Chief Executive Officer, Director

260.28K

--

Dr. Jonathan Mark Hopper

Chief Medical Officer

66.21K

--

Mr. Alan L. Rubino

Independent Director

45.99K

+7.48%

Dr. Paul K. Wotton, Ph.D.

Independent Director

30.60K

+11.68%

Dr. Robert L. Zerbe, M.D.

Independent Chairman of the Board

29.80K

+12.03%

Mr. Michael Halpin

Chief Operating Officer

15.63K

+2.77%

Mr. Kevin F. Mclaughlin

Independent Director

15.10K

--

Ms. Lisa Wright

Independent Director

12.65K

+33.86%

Mr. Sean C. Flynn

Chief Legal Officer

971.00

+105.29%

Ms. Heidi M. Hagen

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Dominick C. Colangelo

President, Chief Executive Officer, Director

260.28K

--

Dr. Jonathan Mark Hopper

Chief Medical Officer

66.21K

--

Mr. Alan L. Rubino

Independent Director

45.99K

+7.48%

Dr. Paul K. Wotton, Ph.D.

Independent Director

30.60K

+11.68%

Dr. Robert L. Zerbe, M.D.

Independent Chairman of the Board

29.80K

+12.03%

Mr. Michael Halpin

Chief Operating Officer

15.63K

+2.77%

收入明細

單位: USD更新時間: 7月6日週日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

MACI

46.30M

88.02%

Epicel

4.96M

9.44%

NexoBrid

1.34M

2.54%

地區USD

名稱

營收

佔比

United States

52.60M

100.00%

業務

地區

業務USD

名稱

營收

佔比

MACI

46.30M

88.02%

Epicel

4.96M

9.44%

NexoBrid

1.34M

2.54%

股東統計

更新時間: 4月20日週日

持股股東

股東類型

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

14.43%

The Vanguard Group, Inc.

6.92%

Brown Capital Management, LLC

5.72%

State Street Global Advisors (US)

4.84%

Fidelity Management & Research Company LLC

4.35%

Other

63.74%

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

14.43%

The Vanguard Group, Inc.

6.92%

Brown Capital Management, LLC

5.72%

State Street Global Advisors (US)

4.84%

Fidelity Management & Research Company LLC

4.35%

Other

63.74%

股東類型

持股股東

佔比

Investment Advisor

54.79%

Investment Advisor/Hedge Fund

45.86%

Pension Fund

2.91%

Research Firm

2.86%

Hedge Fund

1.09%

Individual Investor

1.06%

Bank and Trust

0.92%

Insurance Company

0.10%

Sovereign Wealth Fund

0.06%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

533

54.94M

109.13%

-1.35M

2025Q1

559

55.34M

109.94%

-1.25M

2024Q4

543

54.07M

108.22%

-1.11M

2024Q3

519

52.64M

107.39%

-2.94M

2024Q2

509

52.53M

108.12%

-3.27M

2024Q1

499

52.78M

109.13%

-3.92M

2023Q4

473

53.52M

112.14%

-4.39M

2023Q3

463

53.25M

111.77%

-4.17M

2023Q2

465

51.63M

108.55%

-6.73M

2023Q1

480

52.04M

109.66%

-6.96M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

7.26M

14.43%

-231.46K

-3.09%

Mar 31, 2025

The Vanguard Group, Inc.

3.48M

6.92%

+6.84K

+0.20%

Mar 31, 2025

Brown Capital Management, LLC

2.88M

5.72%

-353.58K

-10.93%

Mar 31, 2025

State Street Global Advisors (US)

2.44M

4.84%

+32.41K

+1.35%

Mar 31, 2025

Fidelity Management & Research Company LLC

2.19M

4.35%

+146.00K

+7.15%

Mar 31, 2025

Conestoga Capital Advisors, LLC

2.06M

4.1%

-7.83K

-0.38%

Mar 31, 2025

Invesco Advisers, Inc.

1.98M

3.94%

+60.96K

+3.17%

Mar 31, 2025

Congress Asset Management Company, LLP

1.48M

2.93%

+22.58K

+1.55%

Mar 31, 2025

GW&K Investment Management, LLC

1.43M

2.85%

+158.47K

+12.44%

Mar 31, 2025

Geneva Capital Management LLC

1.37M

2.71%

+265.96K

+24.18%

Mar 31, 2025

持股ETF

更新時間: 7月6日週日

機構名稱

佔比

ALPS Medical Breakthroughs ETF

1.8%

Invesco S&P SmallCap Health Care ETF

1.45%

AAM Sawgrass US Small Cap Quality Growth ETF

1.2%

SPDR S&P Biotech ETF

0.53%

Invesco S&P SmallCap 600 Pure Growth ETF

0.45%

First Trust NASDAQ Pharmaceuticals ETF

0.45%

OneAscent Small Cap Core ETF

0.34%

SPDR S&P 600 Small Cap Growth ETF

0.32%

WisdomTree US SmallCap Quality Growth Fund

0.32%

Vanguard S&P Small-Cap 600 Growth Index Fund

0.32%

ALPS Medical Breakthroughs ETF

佔比1.8%

Invesco S&P SmallCap Health Care ETF

佔比1.45%

AAM Sawgrass US Small Cap Quality Growth ETF

佔比1.2%

SPDR S&P Biotech ETF

佔比0.53%

Invesco S&P SmallCap 600 Pure Growth ETF

佔比0.45%

First Trust NASDAQ Pharmaceuticals ETF

佔比0.45%

OneAscent Small Cap Core ETF

佔比0.34%

SPDR S&P 600 Small Cap Growth ETF

佔比0.32%

WisdomTree US SmallCap Quality Growth Fund

佔比0.32%

Vanguard S&P Small-Cap 600 Growth Index Fund

佔比0.32%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Vericel Corp

36.260USD

Vericel Corp

36.260

概覽

公司

財務